M&As this week: Strides Pharma Science, Lambda Therapeutic Research, NextPharma
Strides Pharma Science’s step-down subsidiary Strides Pharma has made an arrangement to acquire Vensun Pharmaceuticals for $18m. Strides has agreed…
Strides Pharma Science’s step-down subsidiary Strides Pharma has made an arrangement to acquire Vensun Pharmaceuticals for $18m. Strides has agreed…
Medicines for Malaria Venture (MMV) has entered a collaboration with Drugs for Neglected Disease initiative (DNDi) to create a pandemic…
Alnylam Pharmaceuticals has entered an agreement with Medison Pharma to commercialise its RNAi therapeutic Onpattro in Israel. Onpattro is indicated…
ProKidney has acquired inRegen and its subsidiary Twin City Bio. ProKidney has arranged an initial capital of $75m for financing…
Sanofi has gained access to Biomunex Pharmaceuticals' Plug-and-Play BiXAb platform through a licensing agreement. Sanofi will use the platform to…
Takeda Pharmaceutical has completed an acquisition of Shire for $62bn. The acquisition was approved by the shareholders of Takeda in December…
Sanofi and Regeneron Pharmaceuticals have entered a revised agreement for the development of novel cancer treatments. The revisions build upon…
EQT has agreed to increase its acquisition offer for Karo Pharma to Skr6.15bn ($694m) through the EQT VIII fund. The…
Astellas Pharma has completed the acquisition of Potenza Therapeutics for $405m. Astellas made an upfront payment of $164.6m and has…
GlaxoSmithKline (GSK) and Pfizer have agreed to combine their consumer healthcare businesses with combined annual sales of £9.8bn ($12.7bn) and…